Dr. Jurcic on the Next Steps for Radioimmunotherapy

Video

Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses the next steps for research into radioimmunotherapy.

Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses the next steps for research into radioimmunotherapy.

Radioimmunotherapy holds promise in multiple applications, Jurcic says. Preclinically, this therapy is being applied as conditioning for stem cell transplant. Encouraging results have been seen with beta-emitters.

Radioimmunotherapy may also be beneficial when using alpha particles to reduce toxicity yet gain an anti-tumor effect. In general, increasing the delivery of isotope to tumor cells but avoid toxicity has shown promise in preclinical studies.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,